Medicine and Dentistry
Pediatrics
100%
Child
97%
Encephalitis
88%
Antibody
64%
Disease
62%
Receptor Antibody
60%
Patient
56%
Therapeutic Procedure
51%
Methyldienolone
50%
Dextro Aspartic Acid
50%
Rituximab
49%
Immunotherapy
42%
Plasma Exchange
33%
Modified Rankin Scale
32%
Age
30%
Central Nervous System Disease
29%
Adolescent
28%
Immunoglobulin
27%
Clinical Feature
26%
Consensus
25%
Meta-Analysis
25%
Catatonia
25%
Allergic Encephalitis
25%
Paraneoplastic Cerebellar Degeneration
25%
Corticosteroid
17%
Functional Status
16%
Complication
16%
Follow up
16%
Disease Course
15%
Relapse
12%
Clinician
11%
Medical Record
10%
N Methyl-D-Aspartate Receptor
10%
Serum
10%
Epileptic Seizure
10%
Adverse Event
9%
Female
8%
Intensive Care Unit
8%
Apheresis
8%
Disability
8%
Morbidity
8%
Adult
8%
Recurrent Disease
7%
Epilepsy
6%
Diagnosis
6%
Disease Severity
6%
Cyclophosphamide
6%
Steroid
5%
Adverse Outcome
5%
Etiology
5%
Neuroscience
Pediatrics
75%
Antibodies
40%
Rituximab
34%
Encephalitis
28%
Limbic Encephalitis
25%
Brain
25%
Peripheral Nervous System
12%
Central Nervous System
12%
Nervous System Disorder
12%
Behavior (Neuroscience)
12%
Receptor Antibody
10%
Seizure
10%
Aspartic Acid
10%
Epilepsy
6%
Steroids
5%
Neuroblastoma
5%
Claustrum
5%
Memory Disorder
5%
Intravenous Immunoglobulin
5%
Hu Antibody
5%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
31%
Encephalitis
28%
Antibody
25%
Central Nervous System Disease
25%
N Methyl Dextro Aspartic Acid Receptor Antibody
18%
Diseases
18%
Corticosteroid
9%
Adverse Event
9%
Retrospective Study
6%
Rankin Scale
6%
Disease Severity
6%
Immunotherapy
6%
Cyclophosphamide
6%
Disease Course
6%
Immunoglobulin
6%